AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02179281 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medtronic MiniMed™ 640G system
Description: The MiniMed™ 640G system is indicated for the continuous delivery of insulin, for continuous or periodic monitoring of glucose levels in the fluid under the skin, with a feature for a prediction of low or high glucose episodes.
Study NCT02179281 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic MiniMed™ 640G system
Description: The MiniMed™ 640G system is indicated for the continuous delivery of insulin, for continuous or periodic monitoring of glucose levels in the fluid under the skin, with a feature for a prediction of low or high glucose episodes.
Study NCT04361279 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Injection，100mg/10ml
Study NCT03049644 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical Diagnosis and Therapy
Description: Identification of directional preference.
Study NCT03049644 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Manual Therapy
Description: Mechanically based treatment based on taking joint to end range and thrusting or soft tissue manipulation.
Study NCT02094391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab is to be administered as an IV infusion with a 1.2μm in-line filter (see current version of Investigator's Brochure), using a volumetric pump, at the 3 mg/kg dose, at the ratio and rate specified in the pharmacy manual, to complete the infusion in 90 minutes with a 100 cc normal saline flush at the end. The total dose needed should be diluted to a total volume of 250 mL in 0.9% sodium chloride injection, USP or 5% Dextrose Injection, USP.. The total dose must be calculated using the most recent subject weight (obtained on the same day of, and prior to, the infusion). If the patient weighs more than 125,0 kg, the Coordinating Investigator needs to be contacted to discuss the total infusion volume, infusion rate and duration. Ipilimumab 3 mg/kg will be administered as a single dose intravenously over 90 minutes every 3 weeks for 4 cycles (Weeks W1, W4, W7, W10). A time interval of +/- 3 days is allowed for Ipilimumab administration.
Study NCT04616898 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Venus Bliss
Description: The Venus Bliss™ system is an aesthetic medical device designed to non-invasively reduce subcutaneous adipose tissue of the abdominal area and flanks. It is intended for use in individuals with a Body Mass Index (BMI) of 30 or less. The device consists of an external treatment component and an internal control component. The treatment console is a 1060nm diode laser applicator and a radio frequency applicator. In addition, a Bliss Belt is provided with the system to properly secure one or more applicators to the patient's body during treatment. Finally, the touchscreen monitor is used by the clinician to control the setting display on the main console. It also keeps the clinician informed of the device's status and operating parameters.
Study NCT00718185 — intervention group
Intervention type: PROCEDURE
Intervention: Obtain blood specimens
Description: Obtain blood samples at multiple timepoints.
Study NCT02164110 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Euvichol
Description: * Number of doses and intervals: two doses/Weeks 0 and 2~* Method of administration: oral administration~* Dose of drug to be administered: 1.5 mL/dose
Study NCT02164110 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Shanchol
Description: * Number of doses and intervals: two doses/Weeks 0 and 2~* Method of administration: oral administration~* Dose of drug to be administered: 1.5 mL/dose
Study NCT01896973 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vortx Rx - Histotripsy BPH Device
Description: Non-invasive histotripsy treatment/therapy to be delivered by the surgeon using very low duty cycle ultrasound pulses from outside the patient's body. These pulses form a bubble cloud at the end of the focal area within the prostate which mechanically breaks up the cellular structure of the soft tissue. During treatment, a surgeon is able to direct the bubble cloud throughout the targeted volume using controls located on the device console and using the real-time ultrasound for visualization feedback and control of the bubble cloud location.
Study NCT02248571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: administered as combined therapy with Capecitabine
Study NCT02248571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: administered as combined therapy with Bevacizumab
Study NCT02248571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: administered as combined therapy with Exemestane
Study NCT02248571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: administered as combined therapy with Everolimus
Study NCT02248571 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient questionaires
Description: Patients will fill out questionaires at four specific time points during study treatment to assess patient reported outcome and patients' preference
Study NCT03324841 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Caris MI Profiling
Description: Customized comprehensive biomarker testing
Study NCT00924274 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: rapeseed oil
Description: rapeseed oil in amounts between 14 and 27 g
Study NCT00924274 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: sunflower oil
Description: sunflower oil
Study NCT00468247 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Navigator
Description: Navigator circulatory mgt system
Study NCT01311180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sensoril®
Description: Start with 250 mg po QAM for 7 days and then 250 mg po bid for 7 weeks
Study NCT01311180 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Start with 250 mg po QAM for 7 days and then 250 mg po bid for 7 weeks
Study NCT03542071 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carbohydrate restricted diet
Description: The intervention is implemented by individual face-to-face counseling and mobile-phone counseling by a nutritionist, as well as food bags and recipes suitable for the diet. Targets: fruits and vegetables 500 g/d, fish 2 times/wk, low-fat instead of high-fat meat, red meat ≤ 3 times/wk, low-fat instead of high-fat dairy, high-fibre instead of low-fibre grains, vegetable oils (excluding palm oil and coconut oil) and soft margarine instead of animal fats, moderate reduction of carbohydrates (targets for macronutrients: carbohydrates 40 E%; fat 40 E%; protein 20 E%; dietary fiber 32g, energy intake approximately 2000 kcal/d; protein intake 20 E%; sucrose: \<10 E%; fatty acids: saturated fatty acids \< 10 E%, polyunsaturated fatty acids 5-10 E% and the rest of fat as monounsaturated fatty acids)
Study NCT03542071 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plant-protein based diet
Description: The intervention is implemented by individual face-to-face counseling and mobile-phone counseling by a nutritionist, as well as food bags and recipes suitable for the diet. Targets: fruits and vegetables 1 kg/d; fish 3/wk; high-fibre grains, mainly rye, oat and barley; plant protein instead of meat protein; low-fat fermented dairy instead of other dairy; rapeseed oil and rapeseed-based margarine instead of other fats; no carbohydrate restriction (targets for macronutrients: carbohydrates 55 E%; fat 25 E%; protein 20 E%; dietary fiber 36g, energy intake approximately 2000 kcal/d; protein intake 20 E%; sucrose: \<10 E%; fatty acids: saturated fatty acids \< 10 E%, polyunsaturated fatty acids 5-10 E% and the rest of fat as monounsaturated fatty acids)
Study NCT01002534 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vardenafil
Description: Nasal instillation of Vardenafil
Study NCT01002534 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Nasal instillation of placebo matching in appearance with the Vardenafil instillation
Study NCT03264508 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Heat therapy
Description: 30 sessions (3-4x per week for 8-10 weeks) of hot water immersion in 40°C water, sufficient to raise body core temperature to 38.5°C.
Study NCT03264508 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Thermoneutral water immersion
Description: 30 sessions (3-4x per week for 8-10 weeks) of hot water immersion in 36°C water to prevent changes in body core temperature >0.2°C.
Study NCT00313807 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amino Acid
Description: 7% amino acid infusion
Study NCT00313807 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% Saline Infusion
Study NCT04673526 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic intersphincteric resection
Description: Laparoscopic intersphincteric resection for ultra low rectal cancer in elderly patients
Study NCT04176367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicergoline from China
Description: This is the test arm of China local manufactured Nicergoline
Study NCT04673526 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic abdomino-perineal procedures
Description: Abdominoperineal resection + colostomy in left iliac fossa or perineum
Study NCT03003416 — intervention group
Intervention type: DRUG
Intervention: dexamethasone intravitreal implant
Description: Dexamethasone intravitreal implant (OZURDEX®) as prescribed in clinical practice.
Study NCT05844800 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nuss repair of Pectus Excavatum
Description: The Nuss procedure is a minimally-invasive repair technique of PE (MIRPE), whereby one to three curved metal bars are inserted behind the sternum to correct the shape of the anterior chest wall. The bars are left in situ for three years and then removed.
Study NCT05844800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epidural anesthesia
Description: The Nuss procedure of pectus excavatum repair surgery is performed under general anesthesia. Epidural anesthesia, with a constant infusion of 0.25% bupivacaine, was routinely used and was maintained in the early postoperative period.
Study NCT01930799 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Systematic Screening and Education Regimen
Description: Site will implement a systematic approach to screening bladder health dysfunction in multiple sclerosis patients, providing bladder health management education, and initiating appropriate urologist referrals.
Study NCT00365716 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 20/40/40/20
Description: 20/40/40/20 formulation of quadrivalent human papillomavirus (HPV) (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) vaccine at Day 1, Month 2, and Month 6.
Study NCT00365716 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 40/40/40/40
Description: 40/40/40/40 formulation of quadrivalent human papillomavirus (HPV) (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) vaccine at Day 1, Month 2, and Month 6.
Study NCT00365716 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 80/80/40/80
Description: 80/80/40/80 formulation of quadrivalent human papillomavirus (qHPV) (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) vaccine at Day 1, Month 2, and Month 6.
Study NCT00365716 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo (mcg) (Aluminum Adjuvant)225
Description: placebo containing 225 mcg of aluminum adjuvant per dose at Day 1, Month 2, and Month 6.
Study NCT00365716 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo (mcg) (Aluminum Adjuvant) 450
Description: placebo containing 450 mcg of aluminum adjuvant per dose at Day 1, Month 2, and Month 6.
Study NCT01655823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sham treatment acting as control arm
Study NCT01655823 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sham treatment acting as control arm
Study NCT01655823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetrodotoxin
Description: Comparison of different dosages of Tetrodotoxin
Study NCT00468247 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Conventional care
Description: Conventional haemodynamic care
Study NCT02674737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine, tramadol and flurbiprofen
Study NCT02674737 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tramadol and flurbiprofen
Study NCT02244723 — intervention group
Intervention type: OTHER
Intervention: Lung ultrasound examination
Description: Lung ultrasound (LUS) is increasingly being used at the bedside for assessing alveolar-interstitial syndrome, lung consolidation, pneumonia, pneumothorax, and pleural effusion. It could be an easily repeatable noninvasive tool for diagnosis of ventilator associated pneumonia
Study NCT01893190 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nimodipine
Description: Based upon Investigator Judgement
Study NCT01893190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimodipine Microparticles
Description: Based upon Investigator Judgement
Study NCT02773238 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo FDG PET/CT
Study NCT02773238 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo Tc-99m MAA or Tc-99m DTPA
Study NCT02773238 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Fludeoxyglucose F-18
Description: Undergo FDG PET/CT
Study NCT02773238 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02773238 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo FDG PET/CT
Study NCT02773238 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo functional avoidance radiation therapy
Study NCT02773238 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single Photon Emission Computed Tomography
Description: Undergo Tc-99m MAA or Tc-99m Undergo Tc-99m sulfur colloid SPECT/CT
Study NCT02773238 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Technetium Tc-99m Albumin Aggregated
Description: Undergo Tc-99m MAA SPECT/CT
Study NCT02773238 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Technetium Tc-99m Sulfur Colloid
Description: Undergo Tc-99m sulfur colloid
Study NCT03181165 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate Therapeutic Nutrition
Description: The pharmacist or pharmacy lifestyle coach will work with the participant to develop a diet plan that is low in carbohydrate and energy-restricted based on personal preferences and characteristics. A combination of pre-packaged low-carbohydrate foods and whole foods from pre-specified lists will be used.
Study NCT04355156 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: * All patients randomised to this arm will receive 3mg BD, and increased at 2 weeks to 5mg BD~* Outpatient monitoring at 2 week intervals for a minimum of 8 weeks, with 2 weekly liver contrast ultrasound for assessment of differential blood supply (CEHPI)~* At 8 weeks, after tumour CT RECIST assessments, responders will continue monotherapy. In non-responders, those with disease progression, monotherapy can be continued if patient chooses to continue and if tolerated
Study NCT04355156 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: * All patients receiving placebo will receive tablets to take BD~* Outpatient monitoring at 2 week intervals for a minimum of 8 weeks, with 2 weekly liver contrast ultrasound for assessment of differential blood supply (CEHPI)
Study NCT03153787 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Vaginal probiotic administration according to the standard regimen: 1 tablet (via vaginal) for 5 days after menstruation during the same cycle of the next embryo transfer.
Study NCT02025088 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laser
Description: Patients of this arm will undergo three sessions of laser treatment with an interval of six weeks between them. In each laser session, the non-ablative fractional erbium laser 1340 nm ProDeep (Etheria ® platform/Industra) with tip 100mtz/cm ² will be applied across the face, with a power of 120mJ/mtz time and pulse time of 5ms.
Study NCT02025088 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Microneedling
Description: Patients in this arm will undergo three sessions with microneedling, with an interval of six weeks between them. In the microneedling sessions, the instrument contains 192 microneedles with 2 mm depth, which will be applied to the face in four different directions, making up about 20 movements of coming and going in each direction.
Study NCT00124462 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Realigning knee brace and custom orthodic
Description: A valgus brace, customized functional orthotic for neutral foot position and motion control footwear
Study NCT00124462 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Non realigning knee brace and flat orthodic
Description: A neutral brace that does not have any varus/valgus angulation, control foot orthodic and shoes with flexible midsole
Study NCT01644487 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: self-expanding nitinol stent
Description: A group of patients who will undergo subsequent primary stenting following successful conventional balloon angioplasty
Study NCT01644487 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: balloon angioplasty
Description: A group of patients who will undergo routine conventional balloon angioplasty alone without stenting
Study NCT04176367 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicergoline from Italy
Description: This is the reference arm of Italy originator Nicergoline.
Study NCT01712815 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01712815 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT01712815 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT01712815 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: fluorine F 18-clevudine
Description: Undergo fluorine F 18-clevudine PET/CT scan
Study NCT01712815 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positron emission tomography/computed tomography
Description: Undergo fluorine F18-clevudine PET/CT scan
Study NCT00510315 — intervention group
Intervention type: OTHER
Intervention: Questionnaires, Laboratory tests, Abdominal MRI
Description: Height, weight, waist and hip circumference; systolic and diastolic blood pressure; questionnaires; fasting blood tests: insulin, glucose, lipids (low density lipoprotein (LDL), high density lipoprotein (HDL), triglycerides, LDL pattern, HDL and LDL subspecies), cardiac inflammatory markers (hsCRP, IL-1B, IL-6, IL-10, TNFa), leptin, adiponectin, IGF-1, and IGFBP3; abdominal MRI for visceral and subcutaneous fat measurement
Study NCT02765672 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Driving Behavior Interview
Description: This will be completed thrice, at baseline, post-test1 and at post-test2 (3 months after post test 1)
Study NCT02765672 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Driving Behavior Interview
Description: This will be completed thrice, at baseline, post-test1 and at post-test2 (3 months after post test 1)
Study NCT02765672 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical Driving Assessment
Description: Clinical Driving Assessment includes Optec vision screening, Useful Field of View, Range of Motion, Mini-Mental State Examination (MMSE) and Strength tests. This will be completed thrice, at baseline, post-test1 and at post-test2 (3 months after post test 1)
Study NCT01891968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: 1.3 mg/m2 subcutaneously on days 1, 4, 8 and 11 of a 21 day cycle.
Study NCT00968448 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Respiratory muscle training
Description: Daily training with a handheld device (Pressure threshold loading). 1x50 breaths with adjustments (gradually increasing levels).
Study NCT00968448 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham training
Description: Sham training with same handheld device. 50 breaths daily on the lowest level
Study NCT01069341 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ranibizumab
Description: Intravitreally administered 0.5mg ranibizumab, 3 doses administered monthly.
Study NCT00922207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adefovir
Description: From week -4 to week 2
Study NCT00922207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: From week -4 to week 2
Study NCT00922207 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: From week -4 to week 2